Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896944 | 0.77 | KDM4E (0.32) | KDM4EALOX15MAPK1CASP1HSD17B10 | |
| SCHEMBL25359345 | 0.74 | ALDH1A1 (0.44) | MAPK1CASP1HSD17B10ALDH1A1 | |
| SCHEMBL25359088 | 0.74 | ALDH1A1 (0.44) | MAPK1CASP1HSD17B10ALDH1A1 | |
| SCHEMBL23213758 | 0.69 | CYP1A2 (0.33) | KDM4E | |
| SCHEMBL5896401 | 0.63 | PTGER4 (0.36) | KDM4EMAPK1ALDH1A1 | |
| SCHEMBL23213632 | 0.63 | KMT2A (0.30) | — | |
| SCHEMBL3616241 | 0.62 | KDM4E (0.65) | KDM4EMAPK1CASP1HSD17B10ALDH1A1 | |
| SCHEMBL23213871 | 0.60 | KDM4E (0.34) | KDM4EALOX15MAPK1CASP1HSD17B10 | |
| SCHEMBL5896671 | 0.59 | ALDH1A1 (0.37) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL9227462 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030144-B2 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1499608-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003093263-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | GABRA1, GABRA3, GABRA2 | KDM4E 3196/4885ALOX15 4821/4885MAPK1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.